Status:
COMPLETED
Minimal Residual Disease in Peripheral T-cell Lymphoma
Lead Sponsor:
Washington University School of Medicine
Collaborating Sponsors:
Invivoscribe, Inc.
National Cancer Institute (NCI)
Conditions:
Peripheral T Cell Lymphoma
Eligibility:
All Genders
18+ years
Brief Summary
As T-cell receptor sequencing by LymphoTrack is an assay with high sensitivity that can be performed in peripheral blood, the investigators wish to evaluate the ability of this assay to predict which ...
Eligibility Criteria
Inclusion
- At least 18 years of age.
- Histologically-confirmed peripheral T-cell lymphoma being treated with curative intent. Eligible histologies include, but are not limited to: peripheral T-cell lymphoma, not otherwise specified; angioimmunoblastic T-cell lymphoma; anaplastic large cell lymphoma, ALK negative; and anaplastic large cell lymphoma, ALK positive.
- Plan for treatment with frontline multi-agent anthracycline containing chemotherapy for curative intent (for example, CHOP, CHOEP, EPOCH). A frontline therapy program can include different sequential phases of treatment, including high-dose therapy and autologous stem cell transplantation.
- Availability of pre-treatment test specimen from bone marrow, blood, lymph node, or alternate site to identify tumor-specific clonotype, or willingness to undergo biopsy if sufficient tissue is not available at time of enrollment (e.g. 15 slides from fixed formalin-fixed paraffin embedded tumor tissue
- \*Patients who have less than 15 slides of fixed formalin-fixed paraffin embedded tumor tissue may be considered for enrollment after discussion with the study principal investigator
- Able to understand and willing to sign an IRB approved written informed consent document.
Exclusion
- Receiving second line of therapy or greater.
- Diagnosis of primary cutaneous T-cell lymphoma, extranodal NK-cell lymphoma, acute T-cell lymphoma/leukemia, hepatosplenic T-cell lymphoma.
Key Trial Info
Start Date :
July 31 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 30 2023
Estimated Enrollment :
44 Patients enrolled
Trial Details
Trial ID
NCT03297697
Start Date
July 31 2017
End Date
November 30 2023
Last Update
May 16 2024
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Dana Farber Cancer Institute
Boston, Massachusetts, United States, 02215
2
Washington University School of Medicine
St Louis, Missouri, United States, 63110
3
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065